사본 요약 ( 아래- 영어 원본 참조 )
미국 특허 4049824 ( 1977년 9월20일 ) 이 특허사본은 CMO가 쥐(Mice)로 부터 추출되었으며 이 물질이 포유동물에서 염증을 동반하는 류마티스 증상에 통증완화, 증상개선을 효과를 보인다는 내용. 특허사본 원본 보기 #4,049,824
특허 배경
CMO를 발견한 닥터 디엘은 이웃 집에 류마티스로 고생하는 목수가 살고 있었습니다. 이 목수를 도와줄 목적으로 당시 미 보건성 연구원이었던 닥터 디엘은 스위스 알비노 쥐(Mouse)를 실험하여 관절염을 치료할 수 있는 연구에 착수하였습니다. 당시 프로이즈 부가물 (Freuds Adjunct) 라는 물질을 실험쥐에 투여하면 심각한 관절염을 발생시킬 수 있었습니다. 그래서 관절염이 생긴 실험쥐를 가지고 치료물질을 찾으려는 것이 닥터 디엘의 목적이었습니다.
그런데 실험쥐인 스위스 알비노 쥐는 아무리 이 부가물을 주입해서 관절염이 발생되지 않아서 고민에 빠지게 되었습니다. 그래서 닥터 디엘은 이 쥐에게서 어떤 물질이 관절염을 예방하는 가 하고 의문을 가지고 되었습니다. 닥터 디엘은 결국 스위스 알비노 쥐의 골수에서 하얀색의 왁스 형태를 가진 CMO를 찾아내었습니다. 이 CMO를 관절염이 발생한 다른 실험 쥐에 주입한 결과 관절염의 염증이 없어지고 치료가 되는 것을 목격하게 되었습니다. CMO의 관한 특허는 이 과정과 관련된 것입니다. 이 특허에서 스위스 알비노 쥐에서 CMO (세틸 마이스톨리에이트) 를 분리시키는 과정과 CMO를 주입받은 류마티스 증상을 가진 포유동물이 염증과 다른 증상이 개선되는 과정을 보여주고 있습니다.
CMO의 상업적 생산
닥터 디엘은 처음 CMO를 스위스 알비노 쥐에서 분리해 내었습니다. 그러나 그 양은 너무나 적고 불순물이 많아 상업적인 가치가 없었습니다. 상업적인 가치를 가진 CMO는 1995년도에 소 기름 (Beef Tallow)에서 CMO를 분리하는 기법이 개발되어 생산하게 되었습니다. 소 기름 중99.5% 제거하고 농축과정과 여러 화학과정을 거쳐 순수한 왁스 형태인 CMO로 변화되는데는 많은 첨단기술과 시간 등이 소요됩니다. CMO만 농축되는 것이 아니라 복합체 ( Complex ) 형태로 추출됩니다. CMO의 효과와 품질은 복합체 중 CMO의 함량이 얼마나 포함되느냐에 달려있는 것입니다 1995년에 처음으로 상업화된 CMO 복합체는 CMO의 함량이 불과 3%-4%에 불과하였습니다. 2011년 현재 상업화된 CMO 복합체 중 CMO 순도는 최고 40%에 이릅니다.
TAG •
- 관절,
- 관절염,
- 관절통,
- 류마티스,
- 류마티스 관절염,
- 류마티스 관절염 증상,
- 손관절 통증,
- 손가락 관절염 손가락 통증,
- 엄지 관절 통증,
- 엄지 손가락 관절 통증,
- 퇴행성 관절염,
- 허리통증,
- 보스웰리아,
-
류마티스 관절염
* 아래 정보는 인터넷과 서적을 통하여 발췌된 것입니다. 정확하지 않을 수 있으며 본인증상 진단으로 사용하지 마세요. 관련된 진단은 언제나 전문의사와 상의하세요. 류마티스 관절염은 관절염의 한 형태입니다. 퇴행성 관절염처럼 염증이 있지만 류마티스 ...
Category류마티스란? Views14907
Read More
-
자가 면역질환 루푸스
* 아래 정보는 인터넷과 서적을 통하여 발췌된 것입니다. 정확하지 않을 수 있으며 본인증상 진단으로 사용하지 마세요. 관련된 진단은 언제나 전문의사와 상의하세요 자가 면역질환 루푸스 루푸스는 피부, 근골격, 신장, 심장, 뇌신경, 위장관, 장막 등 다양...
Category류마티스란? Views24323
Read More
-
류마티스와 식이요법
류마티스 음식 요법에 대하여 들어보셨나요? 아마 대부분은 아주 생소하실 겁니다. 류마티스 관절염 환자들은 음식에 대단히 민감합니다. 어떤 종류의 음식은 류마티스 증상을 악화시킵니다. 다음날 이유없이 손발이 퉁퉁 붓고 또 통증이 더 심해졌다면 전날 ...
Category좋은음식 Views17918
Read More
-
닥터 길러(Giller)의 류마티스의 자연요법
발췌 및 요약 Dr. Giller's Natural Prescription (닥터 길러- 자연처방) 페이지 295-300. 닥터 길러는 자연요법에 탁월한 지식과 임상으로 질병에 자연적인 방법을 제시한 현직 의사입니다. 아래에서 제시된 내용은 의학계에서 인정하는 정통적인 치료방...
Category좋은음식 Views15560
Read More
-
Cetyl myristoleate- CMO : 미국 특허 사본 요약 -1977년 9월
사본 요약 ( 아래- 영어 원본 참조 ) 미국 특허 4049824 ( 1977년 9월20일 ) 이 특허사본은 CMO가 쥐(Mice)로 부터 추출되었으며 이 물질이 포유동물에서 염증을 동반하는 류마티스 증상에 통증완화, 증상개선을 효과를 보인다는 내용. 특허사본 원본 보기 #4,...
Category영양 Views66995
Read More
-
샌디아고 면역센터의 CMO과 관절염 임상 연구
※ 샌디아고 면역에서의 CMO 임상 연구는 대단히 중요합니다. 믿을만한 의학기관에서 현직의사가 류마티스와 퇴행성 관절염 환자에게 직접 CMO를 최초로 캡슐형태로 복용했다는데서 큰 의미가 있습니다. 이 연구로 CMO에 대한 안전성 뿐만 아니라 효과까지 ...
Category영양 Views77093
Read More
-
닥터 멕드걸 - 식이요법 (류마티스의 유일한 희망)
한 치과의사는 '1994년 4월 저는 잠깐 선생님을 미시간 그랜드 래피드의 치과 연례 회의에서 잠깐 뵈었습니다. 이 세미나 동안 저는 저의 소아 류마티스를 앓고 있는 저의 4살난 아들에 대하여 여쭈어 본적이 있습니다. 브라이언은 강력한 스테로이드제인...
Category좋은음식 Views57467
Read More
-
No Image
류마티스 환자를 위한 기능성 성분 - CMO
세틸 마이리스톨리에이드 (CMO)의 발견 1910년 버지니아 해리스버그 태생인 닥터 해리 디엘 ( Harry W Diehl ). 미 국립 보건 연구소 ( National Institutes of Health )에서 연구원으로 근무를 했는데 1974년 은퇴할 때까지 무려 500여개의 새로운 합성물질을...
Category영양 Views5995
Read More
-
운동은 류마티스 환자에게 어떻게 중요할가요?
류마티스 환자에게 운동은 어떻게 중요할까요? 류마티스환자에게 운동은 대단히 중요합니다. 관절운동으로 통증이 완화될 뿐만아니라 근육강도를 키울 수 있습니다. 1. 운동은 류마티스 환자 뿐만 아니라 건강사람들의 수명도 증가시킵니다. 2. 정기적인 운동...
Category운동 Views6124
Read More
-
류마티스 환자가 할 수 있는 운동
류마티스 환자가 할 수 있는 운동 운동은 안전한 걸까요? 류마티스 환자에게 안전한 것으로 확인된 운동이 있습니까? 물론이죠. 3가지 정도의 운동이 있습니다. - 스트레칭, 강화운동, 조절운동 스트레칭 가장 간단하고 단순하답니다. 관절과 주변근육의 10초-...
Category운동 Views12507
Read More
-
류마티스 환자가 피해야 할 운동
류마티스 환자가 피해야 할 운동 관절에 무리를 주는 고강도 운동. 예를 들면 조깅이나 역도같은 운동들은 반드시 피해야 할 운동입니다. 류마티스 전문 병원에서는 전문적인 분들의 류마티스 재활에 필요한 운동을 선택해 드립니다 Exercises to Avoid if You...
Category운동 Views4719
Read More
-
류마티스 영양요법
류마티스는 면역제 이상에 의하여 발생되는 질병입니다. 그러므로 류마티스의 영양 요법은 1. 류마티스 환자의 잘못된 면역 기능을 정상으로 바꾸는 영양 성분을 복용하고, 2 류마티스에 의하여 손상된 관절은 연골 영양소에 의하여 회복을 시키는 것에 초점이...
Category영양 Views6536
Read More
A method is described for immunizing against inflammatory rheumatoid arthritis in mammals and for immunizing against and relieving at least one of the symptoms of inflammatory rheumatoid arthritis in mammals.
Chem. Abst. 70 - 69470r (1969)..
Primary Examiner: Friedman; Stanley J.
Attorney, Agent or Firm:
I claim:
1. A method of relieving and inhibiting the symptoms of inflammatory rheumatoid arthritis in mammals which comprises the parenteral administration to a mammal of an effective amount of cetyl myristoleate.
2. A method according to claim 1 wherein said cetyl myristoleate is extracted from the tissues of mice.
3. A method according to claim 1 wherein said cetyl myristoleate is administered with a compatible pharmaceutical carrier.
4. A method according to claim 3 wherein said compatible pharmaceutical carrier is mineral oil.
5. A method according to claim 1 wherein about 0.05-0.75 gm of cetyl myristoleate is administered for each 140-200 gms weight of the animal.
6. A method for preparing a concentrate containing cetyl myristoleate useful for relieving and inhibiting the symptoms of inflammatory rheumatoid arthritis in mammals comprising macerating the tissues of mice to form a macerated material, extracting said macerated material with a solvent to form an extract and concentrating said extract to form said concentrate containing cetyl myristoleate.
7. A method according to claim 6 wherein said macerated material is extracted with methylene chloride.
8. A method according to claim 6 comprising the further step of diluting said extract with a compatible pharmaceutical carrier.
9. A method according to claim 8 wherein said compatible pharmaceutical carrier is mineral oil.
10. The compound, cetyl myristoleate, having the structure
The present invention relates to a method for immunizing against inflammatory rheumatoid arthritis in mammals and for immunizing against and relieving at least one of the symptoms of inflammatory rheumatoid arthritis in mammals by administering parenterally an immunologically or therapeutically effective amount of cetyl myristoleate
to a method of preparing the pharmacologically active cetyl myristoleate by extracting the compound from the tissues of mice and to the compound itself. Osteoarthritis is one of the oldest and most common inflammatory diseases in mammals. It occurs at all ages. Studies show that 97% of all persons over age 60 have an arthritic condition which can be observed by X-ray. The most common symptoms of arthritis are pain, fever and inflammation, and it is the No. 1 crippling disease in man.
An object of the present invention is to provide a method for immunizing against inflammatory rheumatoid arthritis in mammals and to immunize against and relieve the symptoms of inflammatory rheumatoid arthritis in mammals.
Another object of the invention is to inhibit the symptoms, such as pain, fever and inflammation associated with inflammatory rheumatoid arthritis in mammals by administering parenterally cetyl myristoleate extracted from the tissues of mice.
A still further object of the present invention is a method for preparing a compound useful in immunizing against inflammatory rheumatoid arthritis and in inhibiting the appearance of the symptoms thereof by extraction from the tissues of mice.
These and other objects will become apparent in the following detailed description of the invention.
It is well known that Freund's adjuvant will induce poly-arthritis in rats but not in mice. It has been common practice to test various compounds and compositions in laboratories to determine their effectiveness in relieving the symptoms of inflammatory rheumatoid arthritis by administering test compounds or compositions to rats having poly-arthritis induced previously by administering Freund's adjuvant. It was hypothesized that mice must contain some protective factor or mechanism which prevented the inducement of poly-arthritis in mice.
In accordance with the present invention a substance has been isolated from mice which, when administered to rats, essentially prevents the formation of poly-arthritis and the resultant symptoms when the rats are subsequently injected with Freund's adjuvant. The substance was isolated by extracting homogenized whole mice with methylene chloride. Upon purification of this extracted substance it was identified as cetyl myristoleate. The following example describes in greater detail the isolation of the effective substance from mice.
EXAMPLE I
Seventy-nine mice totalling 2300 grams were macerated in an electric blender in batches of about eight mice, each batch being macerated in 400 ml methylene chloride. The final blend was poured into a 4 liter beaker. The blend was stirred until the methylene chloride separated, then the mixture was filtered under light suction through a large Buchner funnel containing filter paper covered by a thin layer of Filter-Cel. The resultant precipitate was washed with two 100 ml portions of methylene chloride. The combined filtrate and washings were separated from a top layer of water after which the methylene chloride was filtered again. This filtrate was concentrated in vacuo to a thin syrup of 167 grams which was treated with four parts of acetone and then left at -5.degree. C. for 3 days with brief stirring each day.
The mixture was filtered using Buchner filter paper with a layer of Filter-Cel and light suction. The precipitate was washed with four 25 ml portions of -5.degree. C. acetone. The combined filtrate and washings were concentrated in vacuo to a thin syrup of 121 grams. This material was dissolved in 500 ml of 20:1 legroin (20.degree.-40.degree. C.), dry ether and chromatographed on 2500 ml 40-325 mesh ASTM silica gel in an appropriate column using the 20:1 legroin-ether mixture as eluent. One 1500 ml "blank" and then eleven 100 ml and six 200 ml fractions were collected.
Fraction Nos. 3-15 inclusive were combined and filtered in vacuo through 120 grams of Darco-X. The filtrate was concentrated in vacuo to a syrup of 0.15 gram. The Darco-X was further washed with several portions of methylene chloride. The 0.15 gram of syrup was dissolved in these washings which were concentrated in vacuo to a syrup of 0.8 gram of crude material. This was chromatographed using 350 ml of silica gel, 70-325 mesh ASTM using 40:1 carbon tetrachloride-ether as eluent.
Fraction Nos. 67-79 of 7 ml each gave 0.4 gram of material which was rechromatographed with 125 ml of silica gel using 60:1 carbon tetrachloride-ether in 2.5 ml fractions.
Fraction Nos. 117-127 gave 0.15 gram of purified syrup which proved to be principally the desired "immunity factor", cetyl myristoleate (v.sub.max.sup.neat 1782 cm.sup.-1). Extensive thin-layer chromatography and frequent bioassays were used throughout to monitor the isolation and purification of the compound.
The following example describes the steps taken to identify the cetyl myristoleate product of Example I.
EXAMPLE II
A mixture of 0.15 gram of the material obtained in Example I was heated with 2 ml of acetone and 3 ml of 10% sodium hydroxide solution under reflux with stirring for fourteen hours and then treated with 0.7 ml of 12 M HCl. Extractions were made with four 5 ml portions of methylene chloride followed by drying with Na.sub.2 SO.sub.4 and then evaporated with methylene chloride in vacuo. The 0.14 gram of material recovered was chromatographed on 140 ml of silica gel with methylene chloride as eluent. A 400 ml and one hundred ten 6 ml fractions were collected.
Fraction Nos. 20-55 gave 40 mg of cetyl alcohol having a melting point of 49.degree.-50.degree. C. after recrystallization from ethanol. The analysis calculated for C.sub.16 H.sub.34 O is
C -- 79.3%
h -- 14.1%
the analysis found was
C -- 79.2%
h -- 14.3%
fraction Nos. 89-110 produced 60 mg of a syrup which was further purified by chromotography. The resultant acid gave (v.sub.max.sup.neat 1712, 1722 (sh cm.sup.-1). The analysis calculated for C.sub.14 H.sub.26 O.sub.2 is
C -- 74.4%
h -- 11.6%
neut. equiv. -- 226.3
What was found is as follows:
C -- 74.1%
h -- 11.9%
neut. equiv. -- 225.5
Both the cetyl myristoleate extracted from the tissues of mice as described in Example I and cetyl myristoleate prepared synthetically as described in Example III have been found to be effective in immunizing against rheumatoid arthritis and the symptoms thereof.
EXAMPLE III
A charge of 150 mg of cetyl alcohol, 150 mg of myristoleic acid, 50 mg of p-toluenesulfonic acid monohydrate of 20 ml of benzene were heated together under reflux conditions for four hours and then washed with a -10% sodium hydroxide solution. The benzene layer was recovered, dried and evaporated in vacuo.
This procedure produced 300 mg of a mobile oil which was identified as cetyl myristoleate (v.sub.max.sup.neat 1782 cm.sup.-1) (nuclear-magnetic-resonance and infrared spectroscopy).
EXAMPLE IV
Following the procedure set out in Example II, 150 mg of cetyl alcohol obtained in Example III and 150 mg of the acid obtained in Example II produced 300 mg of an ester (v.sub.max.sup.neat 1782 cm.sup.-1) which was identified by similar means with the products in Examples I and III.
EXAMPLE V
The cetyl myristoleate or "immunity factor" produced both synthetically and by isolation from whole mice, respectively, were administered parenterally in mineral oil as a compatible carrier to male rats (Sprague Dawley Strain) ranging in weight between 140 and 200 grams. It is not necessary, however, that a carrier be used since cetyl myristoleate is itself an oil.
One set of rats was innoculated subcutaneously with 1.0 ml each of a mixture of mineral oil and 0.05 gm of the immunity factor. Twenty-four hours later the rats were innoculated with Bacto m. Butyricum (Disco 0640-33). A control group received only the Butyricum.
Another set of rats were given 1.0 ml each of a mixture of mineral oil containing 0.075 gm of the synthetically produced cetyl myristoleate. Two days later the rats were innoculated with Bacto m. Butyricum (Disco 0640-33). Another control group received only the Butyricum.
The rats in both control groups developed severe poly-arthritis during the following 10 to 18 day period which persisted through 32 days. All of these rats gradually lost weight.
About 70% of the first group (those treated with "immunity factor" plus Butyricum) were completely protected from the poly-arthritis. They showed no swelling or other symptoms. The other 30% were partially protected during the 32-day period.
All of the second group (those treated with synthetically produced cetyl myristoleate plus Butyricum) were protected from the poly-arthritis and showed a steady gain in weight.
It was found that the purer the cetyl myristoleate the more dramatic were the results in protecting the rats from poly-arthritis. Also, an effective dosage of cetyl myristoleate or "immunity factor" preferably ranges between 0.05 and 0.75 gm for each 140-200 gms weight of the animal. However, doses smaller than and greater than this range will effectively immunize mammals against inflammatory rheumatoid arthritis and immunize against and relieve the symptoms thereof such as pain, fever and inflammation.
Thus havig described the invention in detail, it will be understood by those skilled in the art that certain modifications and variations may be made without departing from the spirit and scope of the invention as described herein and defined in the appended claims.